Literature DB >> 17083538

Ocular findings in four children with mucopolysaccharidosis I-Hurler (MPS I-H) treated early with haematopoietic stem cell transplantation.

Kristina Teär Fahnehjelm1, Alba-Lucia Törnquist, Gunilla Malm, Jacek Winiarski.   

Abstract

PURPOSE: To present visual functions and ocular findings in four children with mucopolysaccharidosis I-Hurler (MPS I-H) treated early with stem cell transplantation (SCT).
METHODS: Clinical ophthalmological evaluations including visual evoked potentials (VEPs) were carried out.
RESULTS: Stem cell transplantation was performed before 20 months of age. Ocular follow-up lasted 1.3-5.6 years (median 4.1 years). Reductions in corneal opacities were observed in all four children post-SCT, but a slight cloudiness persisted. Decreased visual acuity and high hyperopia (median + 6.25 dioptres, range + 4.0 D to + 7.5 D spherical equivalents) were noted in all children. Hyperopia was initially undetected due to dull retinal reflexes and photophobia. Two children developed esotropia, one with amblyopia. Keratometry, performed in two children, demonstrated subnormal values with a mean of 39.33 D (range 37.62-41.00 D). Visual evoked potentials and intraocular pressures were normal. Neither cataract nor dry eye were detected during follow-up.
CONCLUSIONS: Early SCT appears to be beneficial in reducing, but not eliminating, corneal opacities in children with MPS I-H. Subjects are at risk of developing high hyperopia and esotropia. Hyperopia might be caused by the storage of glucosaminoglucans that increase corneal rigidity, thereby straightening the curvature of the cornea and reducing refractive power. As early diagnosis and treatment are very important, paediatric ophthalmologists should remember to rule out MPS I-H in children with corneal opacities.

Entities:  

Mesh:

Year:  2006        PMID: 17083538     DOI: 10.1111/j.1600-0420.2006.00743.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  7 in total

1.  Intrastromal Gene Therapy Prevents and Reverses Advanced Corneal Clouding in a Canine Model of Mucopolysaccharidosis I.

Authors:  Keiko Miyadera; Laura Conatser; Telmo A Llanga; Kendall Carlin; Patricia O'Donnell; Jessica Bagel; Liujiang Song; Joanne Kurtzberg; R Jude Samulski; Brian Gilger; Matthew L Hirsch
Journal:  Mol Ther       Date:  2020-04-11       Impact factor: 11.454

2.  Does enzyme replacement therapy influence the ocular changes in type VI mucopolysaccharidosis?

Authors:  Susanne Pitz; Olufunmilola Ogun; Laila Arash; Elke Miebach; Michael Beck
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-01-22       Impact factor: 3.117

3.  AAV Gene Therapy for MPS1-associated Corneal Blindness.

Authors:  Melisa Vance; Telmo Llanga; Will Bennett; Kenton Woodard; Giridhar Murlidharan; Neil Chungfat; Aravind Asokan; Brian Gilger; Joanne Kurtzberg; R Jude Samulski; Matthew L Hirsch
Journal:  Sci Rep       Date:  2016-02-22       Impact factor: 4.379

4.  Ophthalmologic manifestations in Taiwanese patients with mucopolysaccharidoses.

Authors:  Hsiang-Yu Lin; Wei-Chun Chan; Lee-Jen Chen; Yuan-Chieh Lee; Shu-I Yeh; Dau-Ming Niu; Pao Chin Chiu; Wen-Hui Tsai; Wuh-Liang Hwu; Chih-Kuang Chuang; Shuan-Pei Lin
Journal:  Mol Genet Genomic Med       Date:  2019-03-08       Impact factor: 2.183

5.  Clinical ocular manifestations of Taiwanese patients with mucopolysaccharidoses VI (Maroteaux-Lamy syndrome).

Authors:  Hsu-Ying Lin; You-Hsin Huang; Shao-Yu Lei; Lee-Jen Chen; Shuan-Pei Lin
Journal:  Taiwan J Ophthalmol       Date:  2019-09-12

Review 6.  Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement.

Authors:  Christiane S Hampe; Jacob Wesley; Troy C Lund; Paul J Orchard; Lynda E Polgreen; Julie B Eisengart; Linda K McLoon; Sebahattin Cureoglu; Patricia Schachern; R Scott McIvor
Journal:  Biomolecules       Date:  2021-01-29

Review 7.  Ophthalmological Findings in Mucopolysaccharidoses.

Authors:  Shizuka Tomatsu; Susanne Pitz; Ulrike Hampel
Journal:  J Clin Med       Date:  2019-09-14       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.